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Chapter 1. Preface 
 
The most of life science industry’s activities are driven by R&D in the 
pharmaceutical sector, which accounts for about 85% of the industry’s total R&D 
spending [1]. In such situation, pharmaceutical companies have created many 
revolutionary drugs by using application of life science to provide drastic change 
of social life. In addition, drugs sometimes contribute to advances of life science. 
In the case of tacrolimus, one of the most effective immunosuppressants, the 
detail mechanism of immunosuppression was not revealed at the time of 
discovery. Schreiber et al. elucidated that mechanism [2], and in the process, 
novel and important T cell activation signaling through calcineurin was found. 
These things show that drugs have deep relationships with life sciences, and 
pharmaceutical industry is the major piece on the global bio industry. 
The immune system is the host defense system against pathogenic 
microorganisms, such as bacteria or viruses. The mammalian immune system 
consists of two components, called innate and adaptive immune system. Innate 
immunity is based on the pattern recognition, which detects molecular structures 
that are unique to microorganisms [3]. In contrast, the property of adaptive 
immunity is rigid antigen selectivity mediated by two types of antigen receptor, 
T-cell receptor and B-cell receptor [4]. The numerous diversities of antigen 
receptors are constructed by several mechanisms. Those diversities lead to 
recognize almost any antigenic determinant in a specific manner [5], and effective 
self-protection is achieved. T cells are central player in adaptive immune system, 
because T cells not only can secrete a number of cytokines or chemokines to 
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activate the other immune cells but also can directly attack pathogens or cancer 
cells with antigen specificity. Indeed, in the case of acquired immune deficiency 
syndrome (AIDS), the causative factor of the syndrome HIV infects and destroys 
the T cells, causing deficiency in the immunological surveillance and ultimately 
leading to AIDS [6]. The importance of T cell is clear in adaptive immunity, 
however abnormal T cell activation can result in an autoimmune response against 
self-antigens inducing several autoimmune diseases. Further, T cells also play a 
central role in allograft rejection on organ transplantation [7, 8]. In these cases, 
activation of T cells should be suppressed appropriately, thus T cells are an 
attractive drug target for the treatment of autoimmune diseases or prevention of 
allograft rejection. For example, the calcineurin inhibitors (CNIs) tacrolimus and 
cyclosporine A show potent inhibition of T cell activation and have been used to 
treat several severe autoimmune diseases and to prevent graft rejection in clinical 
settings. However, because these currently available agents exhibit adverse effects 
such as nephrotoxicity [9], I have focused to develop alternative therapeutic 
options that specifically inhibit T cell activation without adverse effects on other 
cell types and organs.  
Protein kinase C (PKC) is a family of multi-modular ~80 kDa 
serine/threonine kinases that regulate cell growth, differentiation, apoptosis, and 
motility. All members of the PKC family consist of the N-terminal regulatory and 
C-terminal catalytic domains, connected by a proteolytically sensitive hinge 
region [10]. PKC consists of conventional PKCs (α, β, and γ), novel PKCs (δ, θ, η, 
and ε) and atypical PKCs (ζ and λ). Regarding activation, conventional PKCs are 
diacylglycerol (DAG)- and Ca2+-dependent, novel PKCs are DAG-dependent but 
Ca2+-independent, and atypical PKCs are DAG- and Ca2+-independent [11-13]. Of 
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the PKC isoforms, PKCθ exhibits a selective pattern of expression in T cells, 
platelets and skeletal muscle [14, 15]. Further, PKCθ is required for signal 
transduction via the three major transcription factors NF-κB, AP-1, and NF-AT, 
particularly in CD3/CD28-induced T cell activation [16-21]. Although the 
proliferation and the cytokine production of murine PKCθ-/- T cells is significantly 
impaired [17], PKCθ is not essential for antiviral immune responses in vivo [22]. 
Sotrastaurin (also known as AEB071) is a first-in-class, orally active and selective 
pan PKC inhibitor. This compound strongly inhibits PKCθ [23] and prevents 
allograft rejection in both rat and non-human primate (NHP) models of 
transplantation [24-26]. The immunosuppressive effects of sotrastaurin have also 
been confirmed in clinical trials for the treatment of psoriasis [27] and prevention 
of renal allograft rejection [28]. However, a near-linear relationship was noted 
between the dose of sotrastaurin and discontinuation of medication in a previous 
study, with the most frequent adverse effects being gastrointestinal disorders, 
particularly diarrhea [28]. Sotrastaurin has also been reported to inhibit not only 
PKCθ, but also PKCα, -β1, -δ, -η, and -ε [23]. Similarly, the PKC inhibitor 
enzastaurin inhibited PKCα, -β, -γ, -δ, -θ, and -ε [29] and also induced 
gastrointestinal disorders in clinical studies [30, 31]. Non-specific PKC inhibition 
might therefore cause adverse gastrointestinal effects. Considering the selective 
expression profile of PKCθ, the selective inhibition of this isoform might achieve 
a suitable balance between immunosuppression and the minimization of other 
systemic side effects. 
AS2521780 was a novel PKCθ inhibitor synthesized by Astellas Pharma Inc., 
through chemical optimization investigation based on the structure-activity 
relationship approach [32]. Although it was revealed that knockout of the PKCθ 
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isoform in mice resulting in defective T cell activation, the outcome of selective 
inhibition of PKCθ by small molecule compounds on T cells has not been 
clarified yet. Gene knockout mice are effective for characterizing the 
physiological functions of target gene, but they might also express phenotypes 
due to unknown compensatory responses or loss of scaffold functions of these 
proteins. Further, species differences of target function cannot be assessed by only 
gene knockout mice approach. Pharmacological approaches using 
isoform-selective inhibitors might therefore clarify the precise functions of 
molecules across the species and their value as drug targets. Taken together, the 
aims of this investigation are to elucidate i) kinase inhibition profile of 
AS2521780, ii) importance of PKCθ in T cell activation signaling across species, 
and iii) whether PKCθ is an attractive drug target for T cell inhibition and for 
treating T cell-mediated autoimmune diseases or prevention of organ rejection 
through animal model evaluation (Fig. 1-1). 
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Fig. 1-1. The aims of investigation on this dissertation. 
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Chapter 2. Investigation regarding pharmacological 
effects of PKCθ inhibitor AS2521780 on T cell 
activation  
 
2.1. Introduction 
Protein kinases are enzymes which catalyze phosphorylation of hydroxyl 
group on serine/threonine or tyrosine residues in target proteins using adenosine 
triphosphate (ATP), and large number (approx. 500) of protein kinases are corded 
in human genome [33]. Since protein phosphorylation plays a prominent role in 
many signal transductions, protein kinases have been considered as an important 
drug targets, and a number of kinase inhibitors have been developed and launched 
especially as anti-cancer drug. Kinases have a homologous kinase domain 
(catalytic domain) in each structure [34], and ATP is used as common substrate , 
thus a kinase inhibitor (mainly ATP-competitive inhibitor) tends to inhibit 
multiple kinases. Such broad kinase inhibition spectrum is sometimes beneficial 
in cancer therapy. For example, regorafenib, a drug for metastatic colorectal 
cancer, inhibits VEGFR, PDGFR-β, KIT, RET, RAF-1, and B-RAF showing good 
efficacy clinically [35, 36]. However, of course broad spectrum causes 
unexpected adverse effects. Indeed, non-specific PKC inhibitor sotrastaurin and 
enzastaurin induced adverse gastrointestinal effects in clinical trials as mentioned 
previous chapter [26, 28, 29], and clinical development of sotrastaurin was 
terminated. Since T cell activation was impaired in PKCθ-/- mice and the 
expression profile of PKCθ was selective, I hypothesized that the selective 
inhibition of PKCθ was enough to exert immunosuppressive effect and beneficial 
7 
 
to minimize systemic side effect. It was therefore very important to clarify the 
inhibition specificity of AS2521780 in this investigation.  
In current study, I have focused to develop alternative therapeutic options 
that specifically inhibit T cell activation using a kinase inhibitor. In this regard, 
since T cells have multiple activation signaling and have multiple functions, it is 
important to check whether which signaling or which function is inhibited by the 
compound. This profiling process is a big help to consider the indication of the 
compound. Further, significant differences in the composition of the immune 
system in other species is known [37], and precise investigation regarding species 
differences can be conducted only by pharmacological approach. Thus, 
confirmation of species differences is the important evaluation item in this study. 
Moreover, oral bioavailability is the other important aspect on drug development. 
Poor metabolic instability or less membrane permeability would cause low 
bioavailability even if the compound has excellent in vitro effectiveness. 
In this chapter, I investigated enzyme inhibition and pharmacological effects 
on T cell activation of AS2521780 through in vitro and in vivo studies, and 
described profile of AS2521780 and the importance of PKCθ in T cell activation 
signaling. 
 
2.2. Materials and Methods 
2.2.1. Animals 
Male Lewis rats were purchased from Charles River Laboratories Japan, Inc. 
(Kanagawa, Japan) and housed in a specific pathogen-free room with free access 
to food and water. Male cynomolgus monkeys, free of simian immunodeficiency 
virus, simian retrovirus, salmonella bacteria, dysentery bacteria and B virus, were 
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purchased from Hamri Co., Ltd. (Ibaraki, Japan) and housed in individual cages. 
They were allowed free access to water and given food once a day. All animals 
were allowed at least 1 week to adapt to their environment before use.  
All animal experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Astellas Pharma Inc. The Tsukuba Research 
Center of Astellas Pharma Inc. is accredited by AAALAC International. 
 
2.2.2. Test compound 
AS2521780 (4-({[(1R,3R,4s,5S)-4-{[(trans-4-hydroxycyclohexyl)methyl] 
amino}adamantan-1-yl]methyl}amino)-2-({[2-(methylsulfanyl)pyridin-3-yl] 
methyl}amino)pyrimidine-5-carbonitrile) was synthesized at Astellas Pharma Inc. 
(Tsukuba, Japan). AS2521780 was dissolved in dimethyl sulfoxide for in vitro 
experiments and in propylene glycol for in vivo experiment. 
 
2.2.3. Protein kinase assays 
Recombinant human PKC isoforms (α, β1, γ, δ, ε, θ, η, and ζ) were 
purchased from Carna Biosciences Inc. (Hyogo, Japan). Inhibition of PKC 
isoforms was measured using a HTRF KinEASE STK S1 kit (Cisbio Bioassays, 
Codolet, France) according to manufacturer’s instructions. Briefly, each kinase 
was incubated in the presence or absence of multiple concentrations of 
AS2521780 (final; 0.03, 0.1, 0.3, 1, 3, 10, and 30 nM for PKCθ, 0.1, 0.3, 1, 3, 10, 
30, 100, 300, and 1000 nM for others) and the STK substrate-biotin (final 250 
nM). ATP was added to start the reaction. ATP concentration for each isoform was 
as follows: α, 10 μM; β1, 30 μM; γ, 3 μM; δ, 60 μM; ε, 10 μM; θ, 30 μM; η, 
30 μM; and ζ, 10 μM. After 30-60 min incubation at room temperature, a 
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monoclonal phosphor-specific antibody labeled with Eu3+-Cryptate and 
streptavidin-XL665 conjugates were added, and then TR-FRET signal which was 
proportional to the phosphorylation level of substrate was measured using HTRF 
plate reader (Artemis, Furuno, Hyogo, Japan).  
Inhibition of 14 human tyrosine (ABL, BTK, CSK, EGFR, EphA1, FAK, 
HER2, IGF1R, ITK, SYK, TEC, TIE2, TRKA, and ZAP70) and 
13 serine/threonine (AKT1, AurC, BMPR1A, CaMK2a, CDK2, CHK1, CK1d, 
GSK3b, JNK3, MLK1, p70S6K, RAF1, and ROCK1) kinases by 1 μM of 
AS2521780 were tested using a Mobility Shift Assay or ELISA, which were 
conducted at Carna Biosciences. 
 
2.2.4. Reporter gene assay 
Human Jurkat E6.1 T cells (ATCC TIB-152) were cultured in RPMI 1640 
(Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Biowest, 
Nuaillé, France) and 1% (v/v) penicillin-streptomycin at 37°C in a humidified 
atmosphere of 5% CO2. Jurkat cells were transiently transfected with pGL3-Basic 
(Promega, Madison, WI, USA)-derived vector containing 445 bp of human IL-2 
promoter region and seeded at 2 x 105 cells per well in 96-well plates. Multiple 
concentrations of AS2521780 (final 1, 3, 10, 30, 100, 300, and 1000 nM), 
anti-human CD3 (1 μg/mL, HIT3a; BD Biosciences Pharmingen, San Jose, CA, 
USA) and anti-human CD28 (1 μg/mL, CD28.2; BD Biosciences Pharmingen) 
were added to cells 16 h post-transfection and incubated for 8 h at 37°C in a CO2 
incubator. Luciferase activities indicating IL-2 transcription levels were detected 
using a Bright-Glo Luciferase Assay System (Promega). 
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2.2.5. T cell proliferation assay 
Human peripheral T cells were purchased from AllCells LLC (Alameda, CA, 
USA). Cells (1 x 105) suspended in RPMI 1640 containing 10% fetal bovine 
serum and 1% (v/v) penicillin-streptomycin were seeded in 96-well flat-bottomed 
plates pre-coated with anti-human CD3 (5 μg/mL, UCHT1; BD Biosciences 
Pharmingen). Multiple concentrations of AS2521780 (final 1, 3, 10, 30, 100, and 
300 nM) and anti-human CD28 (0.5 μg/mL) were added to the wells. After 48 h 
incubation, cell proliferation was detected using intracellular ATP dependent 
CellTiter-Glo Luminescent Cell Viability Assay (Promega). 
 
2.2.6. In vitro cytokine production assay 
Splenocytes from rats and peripheral blood mononuclear cells (PBMCs) 
from cynomolgus monkeys were used as a source of IL-2. For optimal IL-2 
production, rat splenocytes (2 x 105) were incubated with 3 μg/mL of 
concanavalin A (Con A; Funakoshi Corporation, Tokyo, Japan) in RPMI 1640 
containing 10% fetal bovine serum, 50 μM β-mercaptoethanol and 1% (v/v) 
penicillin-streptomycin for 24 h and NHP PBMCs (2 x 105) were incubated with 
25 μg/mL of Con A in RPMI 1640 containing 10% fetal bovine serum and 1% 
(v/v) penicillin-streptomycin for 48 h. To assess the inhibitory effect, multiple 
concentrations of AS2521780 (final 0.3, 1, 3, 10, 30, 100, 300, and 1000 nM) 
were added to cells concurrently with Con A. The concentration of IL-2 in culture 
medium was determined using an ELISA kit (for rat splenocytes, R&D Systems, 
Minneapolis, MN, USA; and for NHP PMBCs, Bio Vender, Karásek, Czech 
Republic) according to manufacturer’s instructions. Brief methods were as 
follows. Medium samples or standards were added in 96-well flat-bottomed plates 
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pre-coated with capture antibody. After 2 h incubation at room temperature, plates 
were washed, and detection antibody was added in each well. After 2 h (for rat) or 
1 h (for NHP) incubation, plates were washed again, and streptavidin-HRP was 
added. Finally, TMB ELISA substrate was added, and then optical density was 
measured. 
Splenocytes from rats were used as a source of IFN-γ, tumor necrosis factor 
(TNF)-α, and IL-17A. Rat splenocytes (2 x 105) were incubated with 5 μg/mL of 
Con A in RPMI 1640 containing 10% fetal bovine serum, 50 μM 
β-mercaptoethanol and 1% (v/v) penicillin-streptomycin for 48 h. Multiple 
concentrations of AS2521780 (final 0.3, 1, 3, 10, 30, 100, 300, and 1000 nM) 
were concurrently added to cells with Con A to assess its inhibition of cytokine 
production. Cytokine concentrations in culture medium were determined using an 
ELISA kit (eBioscience, San Diego, CA, USA for IL-17A and Invitrogen for 
others) according to manufacturer’s instructions. Brief methods were as follows. 
Medium samples or standards were added in 96-well flat-bottomed plates 
pre-coated with capture antibody. After 2 h at 37°C (for IFN-γ) or 2 h at room 
temperature (for TNF-α and IL-17A) incubation, plates were washed, and 
detection antibody was added in each well. After 1 h at 37°C (for IFN-γ) or 1 h at 
room temperature (for TNF-α and IL-17A) incubation, plates were washed again, 
and streptavidin-HRP was added. Finally, TMB ELISA substrate was added, and 
then optical density was measured. 
 
2.2.7. In vivo IL-2 production assay 
Male Lewis rats aged 6 weeks and weighing 190-220 g were used. 
Interleukin (IL)-2 production was induced by injection of Con A dissolved in 
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saline at a dose of 15 mg/kg into the tail vein. AS2521780 (3, 10, and 30 mg/kg) 
or vehicle was orally administered to rats at 1 or 5 h pre-Con A administration. 
Blood was collected and IL-2 plasma concentration was determined using an 
ELISA kit (R&D systems) 3 h post-Con A administration (peak IL-2 production) 
according to manufacturer’s instructions as described in 2.2.6.  
 
2.2.8. Statistical analysis 
All statistical analyses were conducted using GraphPad Prism 5 software 
(GraphPad Software, La Jolla, CA, USA). Data were expressed as means ± 
standard error of the mean (S.E.M). The half maximal inhibitory concentration 
(IC50) values were calculated using sigmoid-Emax non-linear regression analysis. 
Statistically significant differences were determined using Dunnett’s multiple 
comparison test, and P-values less than 0.05 were considered significant. 
 
2.3. Results 
2.3.1. Highly selective inhibition of PKCθ by AS2521780  
AS2521780 (Fig. 2-1) significantly inhibited PKCθ enzymatic activity with 
an IC50 value of 0.48 nM (Table 2-1). The inhibition of other conventional (α, β1, 
and γ), novel (δ, ε, and η) and atypical (ζ) PKC isoforms by AS2521780 was also 
evaluated. The minimum IC50 value of the other PKC isoforms was 18 nM for 
PKCε (Table 2-1), which was approximately 30-fold greater than that of PKCθ, 
and IC50 values of the PKC isoforms except for PKCθ and PKCε were greater 
than 100 nM. Further, kinase panel assays against 14 tyrosine and 13 
serine/threonine kinases (Table 2-2) showed inhibition of only CDK2 enzyme 
activity. However, this effect was moderate, and the IC50 value of 84 nM was 
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more than 100-fold greater than that on PKCθ. Enzyme activities of the other 26 
kinases were not significantly inhibited by 1 μM of AS2521780. These results 
show that AS2521780 is a potent and highly selective inhibitor of PKCθ. 
 
2.3.2. Inhibition of CD3/CD28-induced IL-2 transcription and cell proliferation by 
AS2521780 in human cells  
To clarify the inhibition of T cell receptor (TCR) signal transduction by 
AS2521780, CD3/CD28-induced IL-2 expression in human Jurkat cells and cell 
proliferation in human peripheral T cells were evaluated. Luciferase activity 
reflecting IL-2 transcription was suppressed by AS2521780 in a 
concentration-dependent manner with an IC50 value of 14.0 nM (Fig. 2-2A). 
Further, AS2521780 suppressed CD3/CD28-induced in vitro proliferation of 
human T cells with an IC50 value of 17.0 nM (Fig. 2-2B). These results show that 
PKCθ selective inhibitor AS2521780 exerts potent inhibition of both cytokine 
production and cell proliferation induced by TCR signal activation in human cells.  
 
2.3.3. Inhibition of in vitro and in vivo cytokine production by AS2521780 in rat 
and NHP 
The T cell mitogen Con A induces cytokine production in vitro and in vivo. 
To evaluate the inhibition of IL-2 production in vitro by AS2521780, rat 
splenocytes and NHP PBMCs were stimulated by Con A in the presence of 
AS2521780. AS2521780 suppressed IL-2 production in a 
concentration-dependent manner with an IC50 value of 8.9 nM for rat splenocytes 
and 10.5 nM for NHP PMBCs (Fig. 2-3). Further, an in vivo IL-2 production 
assay using Lewis rats was conducted. AS2521780 was orally administered to rats 
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at doses of 3, 10, and 30 mg/kg at 1 or 5 h pre-Con A injection, and blood samples 
were collected 3 h post-Con A injection. AS2521780 inhibited Con A-induced 
IL-2 production in a dose-dependent manner (Fig. 2-4). Although a dose of 3 
mg/kg of AS2521780 showed slight inhibitory effect of IL-2 production only for 
1 h, a dose of 30 mg/kg of AS2521780 induced near-complete suppression for 5 h. 
Moreover, the effect of AS2521780 on Con A-induced IFN-γ, TNF-α, and IL-17A 
from rat splenocytes was evaluated and suppression of these cytokines observed 
with similar IC50 values against IL-2 (Fig. 2-5). IL-6 was not detected in this 
assay condition (data not shown). These results show that PKCθ selective 
inhibitor AS2521780 exerts potent inhibition of mitogen-induced production of 
multiple cytokines.  
 
2.4. Discussion 
Previous studies using genetically modified mice demonstrated that both 
PKCθ and PKCα have physiological functions in TCR activation. For example, 
CD3/CD28-induced cell proliferation and cytokine production (IL-2 and IFN-γ) 
was significantly impaired in PKCθ-/- T cells [17]. Following the transplantation 
of cardiac allografts, graft survival times in PKCθ-/- mice were significantly 
longer than those in wild type mice [38]. In the type II collagen-induced arthritis 
model, clinical scores and joint pathologies were significantly mitigated in 
PKCθ-/- mice compared to wild type mice [39]. Regarding PKCα, 
CD3/CD28-induced proliferation was impaired in PKCα-/- T cells [40], and 
simultaneous genetic ablation of PKCα and PKCθ resulted in synergistic 
impairment of alloimmune responses [41]. Although these gene knockout mice 
are effective for characterizing the physiological functions of PKC isoforms, they 
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might also express phenotypes due to unknown compensatory responses or loss of 
scaffold functions of these proteins. Further, by gene knockout mice, the 
importance or function of PKC isoforms in T cell signaling can be clarified only 
in mice. Pharmacological approaches using isoform-selective inhibitors might 
therefore clarify the precise functions of molecules across the species and their 
value as drug targets, because function or effect in human should be clarified 
considering clinical application. In this regard, although sotrastaurin is a 
first-in-class and orally active selective PKC inhibitor, it strongly inhibits not only 
PKCθ but also PKCα, -β1, -δ, -η, and -ε. Therefore, sotrastaurin cannot be used to 
elucidate the specific physiological function of PKCθ in T cell signaling by 
pharmacological approach.  
Here, I examined the inhibitory effect of AS2521780 on PKCθ, 7 other PKC 
isoforms, 14 tyrosine and 13 serine/threonine kinases (Tables 2-1 and 2-2). These 
results showed that AS2521780 was a highly selective PKCθ inhibitor. Although 
AS2521780 exhibited relatively potent inhibition of PKCε, as PKCε does not 
appear to be involved in T cell activation signaling [42] and its inhibition was 
approximately 30-fold weaker than that on PKCθ, its impact on T cell activation 
considered to be negligible. Moreover, in contrast to sotrastaurin, AS2521780 did 
not exhibit strong inhibition of PKCα, which is potentially engaged in T cell 
signaling on the basis of gene knockout mice data. Taken together, these findings 
suggest that AS2521780 can be used to investigate the precise physiological 
functions of PKCθ in T cell signaling by pharmacological approach. 
On the basis of these characteristics, I conducted several in vitro experiments 
and found that AS2521780 completely suppressed CD3/CD28-induced T cell 
proliferation or IL-2 production in human cells, and Con A-induced production of 
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IL-2, IFN-γ, TNF-α, and IL-17A (Figs. 2-2, 2-3, and 2-5) in rat and NHP cells. 
Interestingly, IC50 values of these experiments were approximately the same 
regardless of species and stimulus. These results show that PKCθ has fundamental 
roles in a broad range of T cell activation signaling, which is consistent with the 
phenotype of PKCθ-/- mice. Further, although previous studies using PKCα-/- mice 
[40, 41] showed that PKCα contributed to T cell signaling in mice, my results 
demonstrate that selective PKCθ inhibition without an effect on PKCα is 
sufficient for the complete prevention of T cell activation in human, rat or NHP. 
This finding is an important achievement in my pharmacology-based 
investigation. Since the expression of PKCθ is limited compared to that of PKCα 
[14, 15], selective PKCθ inhibition might be a favorable strategy in achieving a 
suitable balance between T cell inhibition and the minimization of other systemic 
effects. 
To investigate the oral activity of AS2521780, I also tested an in vivo 
Con A-induced rat model of IL-2 production. AS2521780 significantly reduced 
plasma IL-2 levels in a dose-dependent manner, with 30 mg/kg of AS2521780 
showing near-complete suppression for 5 h (Fig. 2-4). This result indicates that 
AS2521780 has good oral activity and this compound can be administered per 
orally for evaluation of pre-clinical animal models. 
As summary of this chapter, I show that AS2521780 is highly selective 
PKCθ inhibitor, and reveal the importance of PKCθ in T cell activation signaling 
across several species via a pharmacological approach using AS2521780. As a 
next step, evaluation of AS2521780 in pre-clinical animal models is needed to 
confirm attractiveness of PKCθ selective inhibition as a drug target for T cell 
immunosuppression.  
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2.5. Tables and Figures 
Table 2-1. PKC selectivity of AS2521780. 
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Table 2-2. Inhibition of non-PKC kinases by AS2521780. 
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Fig. 2-1. Structure of AS2521780. 
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Fig. 2-2. Effect of AS2521780 on CD3/CD28-induced IL-2 transcription and cell 
proliferation.  
Luciferase reporter-transfected Jurkat cells were cultured with AS2521780 and 
anti-CD3/CD28 antibodies. After 8 h incubation, luciferase activities reflecting 
IL-2 transcription were measured. Expressed values are mean ± S.E.M of five 
independent experiments conducted in duplicate (A). Human primary T cells were 
cultured with AS2521780 and anti-CD3/CD28 antibodies. After 48 h incubation, 
cell proliferation was detected by a CellTiter-Glo Luminescent Cell Viability 
Assay. Values are expressed as mean ± S.E.M of three independent experiments 
conducted in duplicate. (B). IC50 values were calculated using sigmoid-Emax 
non-linear regression analysis.  
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Fig. 2-3. Effect of AS2521780 on in vitro Con A-induced IL-2 production.  
Rat splenocytes (A) or PBMCs from cynomolgus monkeys (B) cultured with 
AS2521780 and Con A. After 24 h incubation for rat splenocytes or 48 h 
incubation for NHP PBMCs, concentration of IL-2 in supernatant measured by 
ELISA. Values are expressed as mean ± S.E.M of three independent experiments 
conducted in duplicate. IC50 values were calculated using sigmoid-Emax non-linear 
regression analysis. Con A, concanavalin A. 
A
B
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Fig. 2-4. Effect of AS2521780 on in vivo Con A-induced IL-2 production.  
Male Lewis rats (n=4–5) were given a single oral administration of AS2521780 at 
a dose of 3, 10, or 30 mg/kg, or vehicle (propylene glycol). At 1 or 5 h 
post-administration, Con A (15 mg/kg) was injected into the tail vein to induce 
IL-2 production. At 3 h post-Con A injection, blood samples were collected and 
plasma IL-2 concentrations were determined by ELISA. Mean concentration of 
plasma IL-2 in vehicle-administered animals was defined as the control value. 
Values are presented as a mean percentage of the control with S.E.M., and 
significant differences vs. each control shown as ***P <0.001 and **P <0.01 by 
Dunnett’s multiple comparison test. Con A, concanavalin A. 
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Fig. 2-5. Effect of AS2521780 on in vitro Con A-induced cytokine production.  
Rat splenocytes cultured with AS2521780 and Con A. After 48 h incubation, 
concentrations of IFN-γ (A), TNF-α (B), and IL-17A (C) in supernatant measured 
by ELISA. Values are expressed as the mean ± S.E.M of three independent 
experiments conducted in duplicate. IC50 values were calculated using 
sigmoid-Emax non-linear regression analysis. Con A, concanavalin A. 
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Chapter 3. Investigation regarding pharmacological 
effects of AS2521780 on rat adjuvant-induced arthritis 
model 
 
3.1. Introduction 
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized 
with chronic inflammatory synovitis, progressive joint destruction and multiple 
organ manifestations that causes severe disability and mortality. Auto-reactive T 
cells and inflammatory cytokines, such as tumor necrosis factor (TNF)-α, play a 
pivotal role in the pathological processes of RA through the accumulation of 
immune cells and the self-perpetuation of inflammation [43]. There were few 
treatment options with poor outcomes previously, however, the combined use of 
recently developed drugs such as synthetic disease-modifying anti-rheumatic drug 
(DMARD) and a biological DMARD targeting TNF-α has revolutionized 
treatment of RA [43]. Especially, biological DMARDs show quite effective 
anti-inflammatory activities and can induce clinical remission on patients, but 
administration routes of these agents are limited in intravenous or subcutaneous. 
Thus, orally active and effective new agents are still needed.  
Rat adjuvant-induced arthritis model has been used as reliable, reproducible, 
and predictive non-clinical model of RA to evaluate potentially effective drug 
candidates [44, 45]. For example, the CNI tacrolimus have been used for RA 
treatment in clinical settings, and showed significant efficacy in rat 
adjuvant-induced arthritis model through inhibition of CD4+ T cell-dependent 
immune response [46, 47]. Further, tofacitinib, a newly approved Janus kinase 
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inhibitor, also showed dose-dependent inhibition of adjuvant-induced arthritis as 
indicated by decreased paw volume or clinical score [48, 49]. 
As shown in chapter 2, PKCθ selective inhibitor AS2521780 showed potent 
inhibitory effects on T cell activation, including proliferation and cytokine 
production. In this chapter, I investigated pharmacological effects of AS2521780 
on rat adjuvant-induced arthritis model to elucidate the potential of PKCθ 
selective inhibitor as a promising drug candidate for RA treatment. 
 
3.2. Materials and Methods 
3.2.1. Test compound 
AS2521780 was synthesized at Astellas Pharma Inc. and dissolved in 
propylene glycol for oral administration. 
 
3.2.2. Rat adjuvant-induced arthritis model 
Female Lewis rats (Charles River Laboratories Japan, Inc.), aged 7 weeks 
and weighing 140-170 g, were used. Arthritis was induced by injection of 0.5 mg 
of adjuvant (Mycobacterium tuberculosis H37RA, Difco Laboratories, Detroit, 
MI, USA) in 50 μL of liquid paraffin into the right hind footpad (Day 0). 
Untreated rats were used as negative controls. Following arthritis induction, the 
left hind paw volume was measured on Days 9, 15, 22, and 25 by a water 
displacement method using a plethysmometer (MK-550; Muromachi Kikai Co., 
Ltd., Tokyo, Japan). Paw swelling was presented as a change in hind paw volume 
from Day 0. AS2521780 (1, 3, 10, and 30 mg/kg) or vehicle was orally 
administered b.i.d. (twice per day) from Day 1 to 24. On Day 25, the left hind 
paw of each rat was dissected above the ankle joint and fixed in 10% neutral 
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buffered formalin. After decalcification, the paws were embedded in paraffin, 
sectioned longitudinally and stained with hematoxylin and eosin. Plasma IL-6 
concentrations on normal, arthritis control and 30 mg/kg b.i.d. of AS2521780 
treated group were measured in samples collected on Days 8, 13, 20, and 25 using 
an ELISA kit (Invitrogen) according to manufacturer’s instructions. Brief methods 
were as follows. Medium samples or standards were added in 96-well 
flat-bottomed plates pre-coated with capture antibody. After 2 h incubation at 
37°C, plates were washed, and detection antibody was added in each well. After 
1.5 h incubation at room temperature, plates were washed again, and 
streptavidin-HRP was added. Finally, TMB ELISA substrate was added, and then 
optical density was measured. 
All animal experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Astellas Pharma Inc. 
 
3.2.3. Statistical analysis 
Statistical analyses were conducted using GraphPad Prism 5 software. Data 
were expressed as means ± S.E.M. Statistically significant differences were 
determined using Dunnett’s multiple comparison test or Student’s t-test, and 
P-values less than 0.05 were considered significant. 
 
3.3. Results 
After injection of adjuvant, right hind paw (injected side) of animals 
immediately showed inflammatory reaction such as skin redness and edema (data 
not shown). After calming down these first inflammatory responses, left hind paw 
(non-injected side) of animals in the arthritis control group exhibited swelling. 
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Swelling was confirmed at Day 15 post-adjuvant injection and that plateaued by 
Day 25 (Fig. 3-1A). In histopathological analysis at Day 25, severe bone 
destruction and cartilage destruction were observed on all animals of arthritis 
control group (Fig. 3-2B).  
AS2521780 inhibited this left hind paw swelling in a dose-dependent manner, 
and significant inhibition was observed with 3 to 30 mg/kg b.i.d. at Day 25   
(Fig. 3-1A). In particular, AS2521780 at 30 mg/kg b.i.d. almost completely 
suppressed paw swelling and all histopathological change (Fig. 3-2C). Further, 
AS2521780 at 30 mg/kg b.i.d. completely prevented plasma IL-6 elevation   
(Fig. 3-1B). Moreover, although the mean body weight of arthritis control rats 
was markedly lower than that of normal rats due to severe systemic inflammation, 
this weight loss was recovered by AS2521780 in a dose-dependent manner   
(Fig. 3-1C), and statistically significance was confirmed in 30 mg/kg b.i.d. 
treatment group. Of the cytokines tested, only IL-6 was detected in the plasma of 
rats with adjuvant-induced arthritis (data not shown). 
 
3.4. Discussion 
In this rat adjuvant-induced arthritis model, AS2521780 significantly 
prevented paw swelling associated with arthritis in a dose-dependent manner. In 
particular, the highest dose of 30 mg/kg b.i.d. of AS2521780 almost completely 
suppressed paw swelling and histological tissue damage without severe systemic 
side effects on the basis of body weight gain. As these anti-arthritic effects at each 
dose highly correlated with those of the Con A-induced rat model of IL-2 
production (Fig. 2-4). For example, 10 mg/kg of AS2521780 showed more than 
50% inhibition of IL-2 production, and paw swelling was also prevented more 
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than 50%. In addition, 30 mg/kg of AS2521780 completely suppressed both IL-2 
production and paw edema. In addition to IL-2, AS2521780 completely inhibited 
the production of IL-17A and TNF-α from T cells in vitro (Fig. 2-5), and 
suppressed systemic IL-6 production in adjuvant-induced arthritis model 
(Fig. 3-1B). These cytokines would be involved in arthritis pathogenesis because 
biological DMARDs targeting these cytokines exert clear therapeutic effects in 
clinical settings [50-52]. I therefore consider AS2521780 to exert an anti-arthritic 
effect via inhibition of T cell activation and its induced cytokine production. 
To consider clinical application, effective dose is an important aspect. In 
current study, significant inhibition of paw swelling was observed with 3 to 
30 mg/kg b.i.d. of AS2521780. If effective dose for human RA is equal to that on 
rat arthritis model, doses of 3 to 30 mg/kg b.i.d. may be high for oral 
administration. However, in the case of tofacitinib, complete inhibition of paw 
swelling in rat adjuvant-induced arthritis models (while detail protocols were 
different from my experiment) were achieved at doses of 15 to 20 mg/kg per day 
[48, 49], and clinically used (this meant effective) dose was only 5 mg b.i.d. 
(approx. 0.2 mg/kg per day). This discrepancy may be made by the difference of 
oral availability between rats and humans, or difference of pathology between rat 
model and actual human disease. Further, methotrexate, one of effective 
DMARDs, is sometimes concomitantly administered with an investigational drug 
to RA patients [53], and dose of that investigational drug may be reduced through 
synergistic function with methotrexate. Therefore, PKCθ selective inhibitors 
remain an intriguing possibility as drug for RA.  
Taken together, current investigation revealed that PKCθ selective inhibitors 
might be a quite effective therapeutic option for RA as a multiple cytokine signal 
29 
 
inhibitor. In addition, T cells or T cell-secreted cytokines are involved in the 
pathogenesis of the other autoimmune diseases such as systemic sclerosis, 
inflammatory bowel disease or psoriasis [54-57], hence PKCθ selective inhibitors 
have a potential to treat these T cell-mediated autoimmune diseases. Indeed, 
sotrastaurin showed effectiveness in clinical trials for the treatment of psoriasis 
[27]. 
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3.5. Figures 
 
Fig. 3-1. Effect of AS2521780 on adjuvant-induced arthritis in rats.  
Female Lewis rats received an injection of adjuvant-containing liquid paraffin 
into the right foot hind pad (Day 0). Vehicle (propylene glycol) or AS2521780 (1, 
3, 10, 30 mg/kg b.i.d.) was administered from Day 1 to 24. The left hind paw 
(non-injected side) volume (A), concentration of plasma IL-6 (B), and body 
weight (C) are shown. The left hind paw volume was measured by water 
displacement method using a plethysmometer. Plasma IL-6 concentrations were 
measured only on normal, arthritis control and 30 mg/kg b.i.d. of AS2521780 
treated group by ELISA. Data expressed as mean ± S.E.M (n=8). Significant 
differences between arthritis control (vehicle) group shown as ***P <0.001 and 
**P <0.01 by Dunnett’s multiple comparison test. For IL-6 concentration, 
Significant differences between arthritis control (vehicle) group and AS2521780 
treated group shown as ***P <0.001 and **P <0.01 by Student’s t-test.   
A
B C
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Fig. 3-2. Representative micrographs of calcaneal region in rats with 
adjuvant-induced arthritis.  
Figures show hematoxylin and eosin-stained calcaneal regions of left hind paws 
(non-injected side) in a rat with adjuvant-induced arthritis. Bone destruction and 
cartilage destruction were indicated. Representative images of normal (A), 
arthritis control (B), and AS2521780 30 mg/kg b.i.d.-treated rats (C).  
A
0.2 cm
B
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C
0.2 cm
32 
 
Chapter 4. Investigation regarding pharmacological 
effects of AS2521780 on acute rejection in rat and 
non-human primate models of transplantation 
 
4.1. Introduction 
Organ transplantation is the only procedure at this moment to reverse organ 
functions for patients with end-organ failure on such as kidney, heart, liver, lung 
and so on. Although transplanted organs are provided from living or cadaveric 
donor, in either case transplanted organs are allo-derived (same species, non-self), 
and rejection reaction occurs as a result of normal immune-response against 
non-self-antigens. Since T cells are playing a central role in graft rejection 
following solid organ transplantation [7, 58], immunosuppression of T cells is 
necessary to ensure proper graft function by impairment of rejection reaction. 
There were no effective methods to interrupt T cell activation in past days [59], 
thus graft survival time was extremely limited. From the 1950s onwards, 
azathioprine (DNA replication inhibitor), mycophenolate mofetil (MMF; 
lymphocyte proliferation inhibitor), and CNIs were developed [59], and graft 
survival was drastically improved [60]. Consequently, organ transplantation 
became an essential medical procedure. In currently available drugs for 
transplantation, CNIs are the most important anchor-drugs on the basis of their 
significant effectiveness. However, CNIs exhibit adverse effects such as 
nephrotoxicity [9] due to broad expression profile of calcineurin. In addition, 
although CNI minimization protocols that still maintain immunosuppression are 
being developed [61], alternative therapies that specifically inhibit T cell 
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activation without adverse effects on other cell types and organs are still required 
for further improvement of medical transplantation.  
As shown in chapter 2, PKCθ selective inhibitor AS2521780 showed potent 
inhibitory effects on T cell activation, and the possibility was confirmed that 
selective PKCθ inhibition might be a favorable strategy in achieving a suitable 
balance between T cell inhibition and the minimization of other systemic effects. 
In this chapter, I investigated the effect of AS2521780 mono- and combination 
therapy on acute rejection in rat cardiac and NHP renal transplantation models to 
determine the efficacy of the selective inhibition of PKCθ and to elucidate the 
potential of PKCθ selective inhibitor as a promising drug candidate for organ 
transplantation. 
 
4.2. Materials and Methods 
4.2.1. Animals 
Male Lewis (RT1l) rats were purchased from Charles River Laboratories 
Japan, Inc., and ACI (RT1avl) rats from Japan SLC, Inc. (Shizuoka, Japan). Rats 
were housed in a specific pathogen-free room with free access to food and water. 
Male cynomolgus monkeys (Macaca fascicularis) free of simian 
immunodeficiency virus, simian retrovirus, salmonella bacteria, dysentery 
bacteria, and B virus, were purchased from Hamri Co., Ltd. and housed in 
individual cages. Monkeys were allowed water ad libitum and food once a day. 
All animals were allowed at least 1 week to adapt to their environment before 
experiments.  
All animal experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Astellas Pharma Inc. 
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4.2.2. Test compounds 
AS2521780, sotrastaurin, tacrolimus (Prograf® injection or solid dispersion 
formulation [SDF]), and MMF were synthesized at Astellas Pharma Inc. 
 
4.2.3. ACI-to-Lewis rat heterotopic cardiac transplantation 
ACI and Lewis rats aged 8 to 9 weeks were used as cardiac donors and 
recipients, respectively. Heterotopic abdominal cardiac transplantation was 
performed as previously described [62, 63]. Briefly, hearts were transplanted from 
male ACI donors into male Lewis recipients. The donor aorta and pulmonary 
artery were anastomosed, end to side, to the recipient’s abdominal aorta and 
inferior vena cava, respectively. The day of transplantation was designated as 
Day 0. 
AS2521780 (10 and 30 mg/kg as monotherapy, 0.25, 0.5, 1, 3, and 5 mg/kg 
as combination therapy) and sotrastaurin (10, 30, and 50 mg/kg) were dissolved in 
0.1 M HCl containing-propylene glycol and orally administered at 2.5 mL/kg b.i.d. 
(8/16 h intervals). Tacrolimus (Prograf® injection) was diluted with saline and 
intramuscularly administered at 0.02 mg/1 mL/kg q.d. (once daily). MMF was 
suspended in 0.5% methylcellulose solution and orally administered at 
15 mg/5 mL/kg q.d. All test compounds were administered for 14 consecutive 
days immediately after operation. Graft survival was monitored by daily palpation 
until 29 days post-transplantation, and graft rejection was defined as cessation of 
palpable cardiac graft beats.  
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4.2.4. Renal transplantation in non-human primates 
Donor and recipient pairs were established by matching ABO blood type and 
un-matching major histocompatibility complex (MHC) indicated by a one-way 
mixed lymphocyte reaction (stimulation index >2.5). Each animal was then used 
as both a donor and recipient, with one kidney from either animal being 
exchanged between pairs. Renal transplantation was performed using standard 
microsurgical techniques as previously described [64]. Briefly, all donor and 
recipient monkeys were anesthetized and the left kidney of the donor was 
mobilized and excised, along with a long segment of the renal vessels and ureter. 
The renal allograft was then perfused with Euro-Collins solution (4°C) and stored 
in cold saline while the recipients were prepared. The graft kidney was 
transplanted into the lower part of abdomen via end-to-side anastomoses of the 
renal artery to the aorta and the renal vein to the vena cava. End-to-end 
anastomosis of the donor and recipient ureters via ureteral stent was also done 
using 8-0 nylon sutures. Finally, the remaining kidney of each animal was 
removed. To anesthetize animals, tiletamine and zolazepam (USP, Rockville, MD, 
USA) were used for induction, and vaporized isoflurane (Pfizer, New York, NY, 
USA) was used for maintenance. For postoperative care, an analgesic 
(0.02 mg/body buprenorphine, Otsuka Pharmaceutical, Tokyo, Japan), antibiotic 
(250 mg/body cefazolin, Astellas Pharma Inc.), gastroprokinetic agent (1 mg/body 
metoclopramide, Astellas Pharma Inc.), and histamine H2-receptor antagonist as 
gastric acid suppressant (5 mg/body famotidine, Astellas Pharma Inc.) were 
subcutaneously administered twice daily for 3 days post-transplantation. Function 
of transplanted kidneys was monitored via measurement of plasma creatinine 
levels twice per week. Graft rejection was diagnosed based on deterioration of 
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kidney function, which was defined as creatinine level exceeding 10 mg/dL. 
When ultrasonography indicated that creatinine elevation was due to occlusion of 
the ureteral stent, the stent was replaced, and temporarily elevated creatinine 
levels were excluded from the analysis. 
Six previously untreated cynomolgus monkeys were used in the present study. 
AS2521780 (3 mg/2 mL/kg b.i.d., 8/16 h intervals) and tacrolimus (SDF form, 
1 mg/2 mL/kg q.d.) were orally administered to recipients immediately before 
operation, and daily administration continued until the time of graft rejection or 
90 days after operation. At the end of the study, each recipient was euthanized, 
and kidney specimens were collected for histopathological evaluation. Collected 
kidneys were fixed in 10% neutral buffered formalin and embedded in paraffin. 
Sections were stained with hematoxylin and eosin, and rejection was graded 
according to Banff-97 classification [65] with Banff-09 modifications [66].  
 
4.2.5. Statistical analysis 
Graft survival times for both rat cardiac and NHP renal transplantation were 
compared between groups using the log-rank test (Prism 5; GraphPad Software 
Inc.), and P-values less than 0.05 were considered significant. Body weight 
changes in rat transplantation were expressed as mean ± S.E.M, and statistical 
analysis was conducted using Tukey’s multiple comparison test. 
 
4.3. Results 
4.3.1. Effect of AS2521780 monotherapy on rat cardiac transplantation  
In the ACI-to-Lewis, MHC (RT1) fully-mismatched, rat heterotopic cardiac 
transplantation model, grafts only survived until 5 or 6 days post-transplantation 
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in the non-treated group (Table 4-1). Administration of AS2521780 significantly 
prolonged graft survival time, and median survival time (MST) was 14 days for 
the 10 mg/kg b.i.d. group and 20 days for the 30 mg/kg b.i.d. group. In particular, 
in the 30 mg/kg b.i.d. group, heart beats were maintained for all recipients 
throughout the 14-day treatment period, and body weight gain was comparable to 
that of non-treated animals (Fig. 4-1). Administration of sotrastaurin also 
significantly prolonged graft survival time, with an MST of 11 days for the 
10 mg/kg b.i.d. group and 14 days for the 30 mg/kg b.i.d. group. However, 6 of 
the 7 recipients in the 50 mg/kg b.i.d. group died with an aggravated general 
condition by 3 days post-transplantation.  
 
4.3.2. Combinational effects of AS2521780 on eat cardiac transplantation 
The effect of AS2521780 in combination with tacrolimus and MMF on 
cardiac graft survival was investigated in rats. AS2521780 was administered to 
recipient rats concomitantly with each of these drugs at suboptimal dose levels 
where slight prolongation of graft survival was observed. 
In combination with tacrolimus (suboptimal dose: 0.02 mg/kg, 
MST = 7 days), AS2521780 1 mg/kg b.i.d. drastically reduced graft rejection 
(Table 4-2), and the MST (20 days) was comparable to that of AS2521780 alone 
at 30 mg/kg b.i.d. (Table 4-1). Further, all grafts survived for more than 20 days in 
the group receiving AS2521780 at 5 mg/kg b.i.d. in combination with tacrolimus, 
despite drug treatment being withdrawn at 13 days post-transplantation in 
accordance with study design (Table 4-2). 
Treatment of recipients using AS2521780 3 mg/kg b.i.d. in combination with 
MMF 15 mg/kg (suboptimal dose, MST = 8 days) significantly prolonged graft 
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survival compared to MMF monotherapy (Table 4-3). Differences in MST 
between monotherapy with each concomitant drug and combination therapy with 
AS2521780 at 3 mg/kg b.i.d. were 16 days for tacromilus and 13 days for MMF.  
 
4.3.3. Effect of AS2521780 combined with tacrolimus on NHP model of renal 
transplantation 
My laboratory previously reported the effect of tacrolimus on renal 
transplantation in cynomolgus monkeys for graft survival time, graft function 
(plasma creatinine), and histopathology [64]. That report demonstrated that MST 
in vehicle-treated monkeys was 6 days, and that tacrolimus at 1 mg/kg 
significantly prolonged MST to 21 days.  
In the present study, I investigated the effect of AS2521780 at 3 mg/kg b.i.d. 
in combination with tacrolimus at 1 mg/kg in an NHP model of renal 
transplantation using the same protocol as previously described [64]. Six 
cynomolgus monkeys that received renal transplantation followed by 
immunosuppressive therapy with AS2521780 and tacrolimus showed prolonged 
graft survival. MST was 56 days and significantly improved compared to that 
with tacrolimus monotherapy (Table 4-4). In particular, two monkeys survived 
throughout the experimental period (90 days post-transplantation) with 
well-maintained kidney function (Fig. 4-2A). Further, renal histopathological 
evaluation at autopsy revealed that while 6 of the 7 monkeys in the tacrolimus 
monotherapy group exhibited grade IIA, IIB, or III acute T cell-mediated rejection 
(TCMR), 5 of the 6 monkeys in the AS2521780-treated group did not exceed 
grade I acute TCMR (Fig. 4-3, Table 4-4). Regarding safety, body weights 
remained relatively stable (Fig. 4-2B), and no marked changes in levels of plasma 
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hepatic enzymes (aspartate aminotransferase, alanine aminotransferase and 
alkaline phosphatase) were observed (data not shown) in the AS2521780-treated 
group throughout the experimental period. These results demonstrate that 
concomitant use of tacrolimus and AS2521780 potently inhibits T cell-mediated 
rejection in the NHP model of renal transplantation. 
 
4.4. Discussion 
Here, I demonstrated that the selective PKCθ inhibitor AS2521780 prevents 
allograft rejection in both ACI-to-Lewis rat cardiac and NHP renal transplantation 
models. In the ACI-to-Lewis rat cardiac transplantation model, both AS2521780 
and sotrastaurin monotherapy exhibited significantly prolonged graft survival. In 
my rat model, all grafts in the non-treated group survived for only 5 or 6 days 
post-transplantation, and test drug was withdrawn in the treated group at 13 days 
post-transplantation. This graft survival exceeding 20 days therefore indicates that 
acute rejection is nearly completely prevented during the drug-treatment period. 
Six of the 10 grafts survived for more than 20 days in the AS2521780 30 mg/kg 
group. In contrast, graft survival did not exceed 20 days in the sotrastaurin 30 
mg/kg group, which is the maximum tolerated dose (MTD). As shown in chapter 
2, a dose of 30 mg/kg of AS2521780 induced near-complete suppression of 
Con A-induced IL-2 production (Fig. 2-4). Basiliximab, a chimeric monoclonal 
antibody directed against the alpha chain of IL-2 receptor, can significantly reduce 
the incidence of acute rejection in clinical settings [67], this therefore indicates 
IL-2 significantly contribute to rejection reaction. I therefore consider this strong 
inhibitory effect induced by AS2521780 on IL-2 production contribute to the 
marked efficacy observed in the rat transplantation model, at least partially. My 
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group also previously reported the efficacy of MMF [68], which is one of the 
major immunosuppressants currently used to treat transplant rejection and 
autoimmune diseases [69], on rat cardiac allograft rejection using the same 
experimental conditions as the present study. The MST of rats administered 40 
mg/kg (MTD) of MMF monotherapy was 18.5 days, and survival time of half the 
grafts exceeded 20 days, indicating that the effect of AS2521780 30 mg/kg b.i.d. 
is comparable to that of MMF 40 mg/kg in a rat cardiac transplantation model. 
These results suggest that immunosuppression via PKCθ inhibition with an 
isotype-specific small-molecule inhibitor is comparable to current 
immunosuppressive therapy in transplant patients. 
In current clinical settings, the combination of immunosuppressive 
medications such as tacrolimus and MMF is widely used as a maintenance 
therapy to achieve appropriate immunosuppression with limited toxicity after 
kidney transplantation [69]. In the present study, I investigated the efficacy of 
AS2521780 with a suboptimal dose of tacrolimus (0.02 mg/kg) in rat cardiac 
transplantation to consider the clinical application of PKCθ-selective inhibition. 
My results demonstrate the efficacy of AS2521780 with tacrolimus and that the 
MST of rats concomitantly treated with 1 mg/kg of AS2521780 and a suboptimal 
dose of tacrolimus was comparable to that of MMF 20 mg/kg and tacrolimus [68]. 
I also confirmed that 1 mg/kg of AS2521780 did not affect the plasma 
concentration of tacrolimus (data not shown), thus this additive effect would exert 
via biologically. Regarding monotherapy, AS2521780 at 30 mg/kg b.i.d. was 
required to exert an effect comparable to MMF at 40 mg/kg. However, in the case 
of combination therapy with tacrolimus, only AS2521780 at 1 mg/kg b.i.d. 
exerted an effect comparable to MMF at 20 mg/kg. These results suggest that the 
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efficacy of a PKCθ selective inhibitor and tacrolimus is more effective than that 
of MMF and tacrolimus. 
To identify other immunosuppressive regimens using the selective inhibition 
of PKCθ, I further investigated the combination of AS2521780 with MMF in a rat 
model of cardiac transplantation. These results showed that concomitant 
administration of 3 mg/kg b.i.d. of AS2521780 with a suboptimal dose of MMF 
(15 mg/kg) significantly prolonged graft survival compared to MMF monotherapy. 
MST in rats with a suboptimal dose of tacrolimus (7 days) was comparable to that 
in rats with a suboptimal dose of MMF (8 days), and MST in rats treated with 
3 mg/kg b.i.d. of AS2521780 combined with tacrolimus or MMF were also 
comparable at 23 or 21 days, respectively. As the combination of a selective 
PKCθ inhibitor with tacrolimus or MMF is clearly effective, selective PKCθ 
inhibitors might be versatile and useful in clinical settings. 
Rat models of transplantation extremely useful for clarifying the effects of 
drugs on the immune system. However, these models contain major limitations, as 
they do not fully reflect the human immune system [70]. Recently, NHP transplant 
models have become increasingly common for the evaluation of new 
immunosuppressive agents before moving to clinical trials. In the present study, 6 
cynomolgus monkeys were used to evaluate the combination effect of AS2521780 
and tacrolimus in an NHP model of renal transplantation. These results 
demonstrated that concomitant use of tacrolimus and AS2521780 exerts potent 
inhibition of graft rejection, particularly for T cell-mediated rejection, with 
histopathological confirmation.  
Sotrastaurin has been reported to prolong the survival times of kidney 
allografts in cynomolgus monkeys [24], and immunosuppression via sotrastaurin 
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has been confirmed in clinical trials for anti-rejection therapy following kidney 
transplantation [28]. In this clinical trial, however, a near-linear relationship was 
noted between the dose of sotrastaurin and discontinuation of study medication. 
Thus, the adverse effects associated with sotrastaurin might prevent its full 
efficacy from being reached. Indeed, in my rat experiments, 30 mg/kg b.i.d. of 
sotrastaurin significantly prolonged graft survival. However, 50 mg/kg b.i.d. was 
lethal, and the maximum prolongation of graft survival following administration 
of sotrastaurin was significantly shorter than that of AS2521780 (Table 4-1). 
AS2521780 was well tolerated in the present study (Figs. 4-1 and 4-2B). Further, 
in the preliminary 2-week toxicological study using cynomolgus monkeys, 
toxicological findings were not observed when AS2521780 was administered at 
10 mg/kg (data not shown). These findings suggest that compounds with selective 
PKCθ inhibition might exhibit improved efficacy and safety profiles compared to 
sotrastaurin.  
In summary of this chapter, the investigation regarding AS2521780 in a rat 
model of cardiac transplantation and NHP model of renal transplantation 
demonstrates the potential of PKCθ as a new drug target for organ transplantation. 
As AS2521780 was well tolerated and the dose of tacrolimus or mycophenolate 
mofetil can be reduced when used in combination with this drug, 
immunosuppressive regimens containing selective inhibitors of PKCθ might have 
good safety profiles. 
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4.5. Tables and Figures 
Table 4-1. Effect of AS2521780 and sotrastaurin monotherapy on ACI-to-Lewis 
rat cardiac transplantation. 
 
aMST; median survival time 
bPropylene glycol was administered. 
cP-value was calculated by log-rank test compared to non-treated group. 
dP-value was calculated by log-rank test compared to 30 mg/kg b.i.d. of 
sotrastaurin-treated group. 
eDied with functioning graft. 
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Table 4-2. Effect of AS2521780 concomitant treatment with tacrolimus on 
ACI-to-Lewis rat model of cardiac transplantation. 
 
aMST; median survival time 
bP-value was calculated by log-rank test compared to tacrolimus monotherapy. 
cPropylene glycol was administered. 
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Table 4-3. Effect of AS2521780 concomitant treatment with mycophenolate 
mofetil (MMF) on ACI-to-Lewis rat model of cardiac transplantation. 
 
aMST; median survival time 
bP-value was calculated by log-rank test compared to MMF monotherapy. 
cPropylene glycol was administered.
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Table 4-4. Effect of AS2521780 concomitant treatment with tacrolimus on NHP model of renal transplantation. 
 
NHP; non-human primate, TCMR; T cell-mediated rejection, IF/TA; interstitial fibrosis/tubular atrophy 
aMST; median survival time 
bP-value was calculated by log-rank test compared to 1 mg/kg of tacrolimus-treated group. 
cData of graft survival on these animals were previously reported from my laboratory [64]. Histopathological analysis using Banff 
classification was newly conducted.  
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Fig. 4-1. Changes in body weight in rat model of cardiac transplantation. 
Graft survival times of animals are shown in Table 4-1. Data are expressed as 
mean ± S.E.M. No significant differences were noted using Tukey’s multiple 
comparison test among all time-points and treatment groups. 
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Fig. 4-2. Changes of parameters in NHP model of renal transplantation. 
Figures show plasma creatinine concentration (A) and body weight (B) of 
renal-transplanted cynomolgus monkeys, which were concomitantly treated with 
3 mg/kg of AS2521780 and 1 mg/kg of tacrolimus. Plasma creatinine levels were 
measured twice per week and body weights were measured once per week. 
Matching symbols indicate the same individuals across two figures. NHP; 
non-human primate.  
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Fig. 4-3. Representative micrographs of transplanted kidneys in AS2521780 and 
tacrolimus-treated monkeys at autopsy.  
(A-C) Histology of a monkey that survived 77 days. Each photo shows acute 
TCMR grade IA with mononuclear cell interstitial infiltration (A), chronic active 
TCMR with arterial intimal hypertrophy (B), and IF/TA grade III (C).  
(D, E) Histology of a monkey that survived 90 days. Each photo shows chronic 
active TCMR with arterial intimal hypertrophy (D), and IF/TA grade II (E). Scale 
bars indicate 50 μm. TCMR; T cell-mediated rejection, IF/TA; interstitial 
fibrosis/tubular atrophy. 
A B
C D
E
50 μm 
50 μm 50 μm 
50 μm 50 μm 
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Chapter 5. Concluding remarks 
 
To provide better immunosuppressant into clinical settings, I have focused to 
develop alternative therapeutic options that specifically inhibit T cell activation 
without adverse effects on other cell types and organs. In this regard, the aims of 
this investigation are to elucidate i) kinase inhibition profile of AS2521780, ii) 
importance of PKCθ in T cell activation signaling across species, and iii) whether 
PKCθ is an attractive drug target for T cell inhibition and for treating T 
cell-mediated autoimmune diseases or prevention of organ rejection through 
animal model evaluation.  
As described in chapter 2, I first examined kinase selectivity of AS2521780, a 
newly synthesized PKCθ inhibitor, against 7 other PKC isoforms and 14 tyrosine 
and 13 serine/threonine kinases to confirm whether this compound could be used 
as a PKCθ selective inhibitor for further investigations. Results showed that 
AS2521780 was a highly selective PKCθ inhibitor and indicates that AS2521780 
can be used to investigate the physiological functions of PKCθ in T cell signaling. 
On the basis of these characteristics, I conducted several in vitro experiments and 
found that AS2521780 completely suppressed CD3/CD28-induced T cell 
proliferation or IL-2 production in human cells, and Con A-induced production of 
several cytokines in rat and NHP cells. IC50 values of these experiments were 
approximately the same regardless of species and stimulus. My investigation via 
pharmacological approach shows that PKCθ has fundamental roles in a broad 
range of T cell activation signaling across several species. In addition, since my 
results demonstrate that selective PKCθ inhibition without an effect on PKCα is 
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sufficient for the complete prevention of T cell activation, selective PKCθ 
inhibition might be a favorable strategy in achieving a suitable balance between T 
cell inhibition and the minimization of other systemic effects.  
In chapters 3 and 4, effects of AS2521780 in pre-clinical animal models was 
investigated to confirm attractiveness of PKCθ as a drug target for T cell 
immunosuppression. In chapter 3, I investigated effects of AS2521780 on 
adjuvant-induced arthritis in rats, which is a model of RA, to investigate whether 
PKCθ selective inhibition can potentially ameliorate T cell-mediated autoimmune 
diseases. As a result, AS2521780 inhibited paw swelling in a dose-dependent 
manner, and significant inhibition was observed with 3 to 30 mg/kg b.i.d. These 
results highlight the potential of a PKCθ selective inhibitor in the treatment of RA 
or other T cell-mediated autoimmune diseases. Further, to elucidate the possibility 
of PKCθ selective inhibitors for other therapeutic indication, I investigated the 
effect of the PKCθ selective inhibitor AS2521780 in mono- and combination 
therapies on acute rejection in ACI-to-Lewis rat cardiac and NHP renal 
transplantation models, and results were described in the chapter 4. Data 
demonstrate that the potential of PKCθ as a new drug target for organ 
transplantation with good safety profiles.  
As summary of this dissertation, I summarize important findings in current 
investigation as follows; i) AS2521780 is a potent and selective PKCθ inhibitor, 
ii) PKCθ has fundamental roles in a broad range of T cell activation signaling 
across several species, iii) PKCθ selective inhibitor effectively prevents 
development of rat adjuvant-induced arthritis with safety, and iv) PKCθ selective 
inhibitor effectively prevents rejection reaction on rat and NHP models of 
transplantation with safety (Fig. 5-1). Taken together, these findings show that the 
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developmental possibility of PKCθ selective inhibitors as effective novel 
immunosuppressants, and this is the first experimental output regarding the 
potential clinical application of PKCθ selective inhibitor. Although many 
researchers have made effort to explore novel immunosuppressant, there are only 
a few successes. In particular, limited to selective kinase inhibitor, only 2 drugs 
Janus kinase inhibitor tofacitinib and mTOR inhibitor rapamaycin have been 
launched. Thus, my current finding, PKCθ selective inhibitor can exert strong 
immunosuppression without toxicity, are quite noteworthy and I believe my 
investigation clearly contribute to the progress of biotechnology and bioindustrial 
sciences. Further, after my publication, the other researchers on pharmaceutical 
companies reported profiles of their PKCθ selective inhibitors with different 
chemical structures, and they showed similar T cell inhibitory effects and 
anti-arthritic effect in rat models [71, 72]. These findings support my discovery 
that PKCθ is a valuable drug target of immunosuppressants. Moreover, although I 
focused PKCθ as a target for immunosuppressant, recent investigations revealed 
the potential of the other clinical indications of PKCθ inhibitors, such as 
anti-cancer or anti- human immunodeficiency virus [73, 74]. I strongly hope my 
investigation will lead to development of new specific drug, and that drug will 
provide drastic change of social life. 
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Fig. 5-1. Summary of findings on this dissertation. 
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